- Trials with a EudraCT protocol (86)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
86 result(s) found for: Interleukin 8.
Displaying page 1 of 5.
EudraCT Number: 2020-001172-15 | Sponsor Protocol Number: APN01-01-COVID19 | Start Date*: 2020-04-08 |
Sponsor Name:APEIRON Biologics AG | ||
Full Title: Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19 | ||
Medical condition: Severe COVID-19 POSITIVE hospitalized male or female, between 18 and ≤ 80 years of age | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) DK (Completed) AT (Completed) GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2015-002202-37 | Sponsor Protocol Number: 2015-115 | Start Date*: 2016-01-06 |
Sponsor Name:radboudumc | ||
Full Title: Pilot study: Is concomitant administration of lidocaine during oxaliplatin infusion able to prevent pain as a result of oxaliplatin induced acute neuropathy? | ||
Medical condition: Acute oxaliplatin induced neuropathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019952-35 | Sponsor Protocol Number: CS001P3 | Start Date*: 2010-09-14 |
Sponsor Name:CEL-SCI Corporation | ||
Full Title: A Phase III, Open-label, Randomized, Multi-center Study of the Effects of Leukocyte Interleukin, Injection [Multikine] Plus Standard of Care (Surgery + Radiotherapy or Surgery + Concurrent Chemorad... | ||
Medical condition: Subjects with Advanced Primary Sqamous Cell Carcinoma of the oral Cavity/Soft Palate | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) PL (Completed) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) RO (Ongoing) HR (Ongoing) ES (Prematurely Ended) IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-001188-22 | Sponsor Protocol Number: MIMMA | Start Date*: 2013-09-12 |
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA | ||
Full Title: Interleukin 2 and zolendronic acid as maintaining treatment in multiple myeloma patients after autologous bone marrow transplant | ||
Medical condition: Multiple Myeloma patients underwent to autologous bone marrow transplant | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003858-33 | Sponsor Protocol Number: AM0010-301 | Start Date*: 2017-05-12 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Followi... | |||||||||||||
Medical condition: Advanced Metastatic Pancreatic Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) ES (Completed) DE (Completed) BE (Completed) GB (Completed) PL (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002478-20 | Sponsor Protocol Number: PRECISESTUDY | Start Date*: 2022-03-31 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI FERRARA | |||||||||||||
Full Title: IDENTIFICATION OF SYNOVIAL BIOMARKERS OF RESPONSE TO IXEKIZUMAB IN REFRACTORY PSORIATIC ARTHRITIS: THE PRECISE STUDY. | |||||||||||||
Medical condition: PSORIATIC ARTHRITIS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002701-26 | Sponsor Protocol Number: 64304500CRD2002 | Start Date*: 2021-01-12 | |||||||||||
Sponsor Name:JANSSEN CILAG INTERNATIONAL NV | |||||||||||||
Full Title: A Phase 2a Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Proof-of-Concept Clinical Study to Evaluate the Safety and Efficacy of JNJ-64304500 as Add-on Therapy to Standa... | |||||||||||||
Medical condition: Active Crohn's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000649-77 | Sponsor Protocol Number: C0743T26 | Start Date*: 2009-02-06 | |||||||||||
Sponsor Name:Centocor BV | |||||||||||||
Full Title: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects with Moderately to Severely Active... | |||||||||||||
Medical condition: Moderately to Severely Active Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) GB (Completed) BE (Completed) ES (Completed) AT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003028-59 | Sponsor Protocol Number: NL62684.091.17 | Start Date*: 2018-06-06 |
Sponsor Name:Radboud University Medical Centre | ||
Full Title: Treatment with Recombinant human Interleukin 1 receptor antagonist (Anakinra) in patients with Anaplastic Thyroid Cancer: a proof of concept study | ||
Medical condition: Anaplastic Thyroid Carcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-006656-14 | Sponsor Protocol Number: MH002-PC-201 | Start Date*: 2022-06-22 | |||||||||||
Sponsor Name:MRM Health NV | |||||||||||||
Full Title: Exploratory Study to Evaluate Safety, Mechanistic and Clinical Effects of MH002 in Subjects with Acute Pouchitis | |||||||||||||
Medical condition: Acute Pouchitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005717-36 | Sponsor Protocol Number: 1645-CI-057 | Start Date*: 2012-06-14 |
Sponsor Name:Instituto de Investigación Sanitaria La Fe | ||
Full Title: Extremely low gestational age neonates randomly an assigned to be blindly resuscitated with 21% vs. 60% oxygen: influence upon mortality and chronic conditions in the neonatal period. | ||
Medical condition: Preterm infants aged 30 weeks or less, who need resuscitation / stabilization maneuvers with positive pressure ventilation immediately after birth | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002126-20 | Sponsor Protocol Number: PID13341 | Start Date*: 2018-08-13 | ||||||||||||||||
Sponsor Name:University of Oxford | ||||||||||||||||||
Full Title: Interleukin-2 therapy of Autoimmunity in Diabetes: ITAD | ||||||||||||||||||
Medical condition: Type 1 Diabetes | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004511-21 | Sponsor Protocol Number: RC-2007-01 | Start Date*: 2007-08-01 | |||||||||||
Sponsor Name:Queen Mary University London | |||||||||||||
Full Title: Upfront Sunitinib (SU011248)® therapy followed by surgery in patients with metastatic renal cancer: a pilot Phase II study [SuMR] | |||||||||||||
Medical condition: The current standard treatment in patients with metastatic renal cancer includes nephrectomy followed by immune therapy with either interleukin 2 (rIL-2) or interferon (IFN-α). Unfortunately, resp... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002744-74 | Sponsor Protocol Number: F3-IROzono-COVID-19 | Start Date*: 2022-06-23 | |||||||||||
Sponsor Name:Sociedad Española de Ozonoterapia - SEOT [...] | |||||||||||||
Full Title: Effect of rectal ozone therapy on the clinical progress of hospitalized patients with mild-moderate covid19 infection: A triple- blind, randomized controlled trial. | |||||||||||||
Medical condition: COVID-19 infection requiring hospitalization | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002031-29 | Sponsor Protocol Number: R7257-RAA-1947 | Start Date*: 2020-11-05 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: A PHASE 1/2 STUDY OF REGN7257 (ANTI-INTERLEUKIN 2 RECEPTOR SUBUNIT GAMMA [IL2RG] MONOCLONAL ANTIBODY) IN PATIENTS WITH SEVERE APLASTIC ANEMIA THAT IS REFRACTORY TO OR RELAPSED ON IMMUNOSUPPRESSIVE ... | |||||||||||||
Medical condition: SEVERE APLASTIC ANEMIA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004810-41 | Sponsor Protocol Number: MV28073 | Start Date*: 2012-04-18 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: An international, multicenter, open-label study evaluating sustained virological response and safety with Boceprevir in triple combination therapy with Peginterferon alfa-2a (40KD) and Ribavirin in... | |||||||||||||
Medical condition: Genotype 1 CHC virus infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) HU (Completed) ES (Completed) PL (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003444-30 | Sponsor Protocol Number: C0743T12 | Start Date*: 2007-05-15 | |||||||||||
Sponsor Name:Centocor B.V. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis | |||||||||||||
Medical condition: Moderate to Severe Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) DE (Completed) BE (Completed) NL (Completed) GB (Completed) AT (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003561-16 | Sponsor Protocol Number: TAK-242/01-04-TL-242-011 | Start Date*: 2005-12-21 | |||||||||||
Sponsor Name:Takeda Europe R&D Centre Ltd | |||||||||||||
Full Title: A Pivotal, Multicentre, Multinational, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-242 in Adults with Severe Sepsis | |||||||||||||
Medical condition: Severe sepsis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) FI (Prematurely Ended) AT (Prematurely Ended) CZ (Prematurely Ended) SE (Prematurely Ended) ES (Completed) PT (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001647-12 | Sponsor Protocol Number: ARB-001467-003 | Start Date*: 2018-02-06 | |||||||||||
Sponsor Name:Arbutus Biopharma Corporation | |||||||||||||
Full Title: A Phase 2a, Open-Label, Study Evaluating the Safety and Anti-Viral Activity of ARB-001467 in Non-Cirrhotic, HBeAg-Negative Subjects with Chronic HBV Infection (Genotype A or B) in Combination with ... | |||||||||||||
Medical condition: Hepatitis B virus e-antigen (HBeAg)-negative subjects with chronic hepatitis B virus infection (CHB) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004421-28 | Sponsor Protocol Number: A2171084 | Start Date*: 2006-11-09 | |||||||||||
Sponsor Name: | |||||||||||||
Full Title: A SIX MONTH, OPEN-LABEL OUTPATIENT, RANDOMIZED PARALLEL GROUP TRIAL ASSESSING THE IMPACT OF DRY POWDER INHALED INSULIN (EXUBERA®) ON GLYCEMIC CONTROL COMPARED TO INSULIN GLARGINE (LANTUS®) IN PATIE... | |||||||||||||
Medical condition: Diabetes Mellitus type II (not insulin independent) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) SE (Completed) FR (Completed) BE (Completed) FI (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.